Abstract
Tumor microenvironment (TME) cells are important elements in tumor tissue. There is increasing evidence that they have important clinical pathological significance in predicting tumor clinical outcomes and therapeutic effects. However, no systematic analysis of TME cell interactions in glioblastoma (GBM) has been reported. We systematically analyzed the transcriptional sequencing data of GBM to find an immune gene marker to predict the clinical results of GBM. First, we downloaded the expression profiles and clinical follow-up information of GBM from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). CIBERSORT was used to evaluate the infiltration mode of TME in 757 patients, systematically correlated TME phenotype with genomic characteristics and clinicopathological characteristics of GBM, defined four TME phenotypes, and TMEScore was constructed using algorithms such as random forest and principal component analysis. There is a significant correlation between TMEScore and age of onset. High TMEScore samples are characterized by immune activation, TGF pathway activation, and high expression of immune checkpoint genes, while low TMEScore samples are characterized by high-frequency IDH1 and MET mutations. Therefore, a comprehensive landscape depicting the TME characteristics of GBM may help explain GBM’s response to immunotherapy and provide new strategies for cancer treatment. In this study, TMEScore can be used as a new prognostic marker to predict the survival of GBM patients, and as a potential predictor of immune checkpoint inhibitor response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17:218. https://doi.org/10.1186/s13059-016-1070-5
Boillaud E, Molina G (2015) Are judgments a form of data clustering? Reexamining contrast effects with the k-means algorithm. J Exp Psychol Hum Percept Perform 41:415–430. https://doi.org/10.1037/a0038896
Burr ML et al (2017) CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549:101–105. https://doi.org/10.1038/nature23643
Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S, Wu A (2016) Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology 86:2226–2234. https://doi.org/10.1212/WNL.0000000000002770
Cohen AL, Holmen SL, Colman H (2013) IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 13:345. https://doi.org/10.1007/s11910-013-0345-4
Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy Science 342:1432–1433. https://doi.org/10.1126/science.342.6165.1432
Cristescu R et al (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362:eaar3593. https://doi.org/10.1126/science.aar3593
Ellor SV, Pagano-Young TA, Avgeropoulos NG (2014) Glioblastoma: background, standard treatment paradigms, and supportive care considerations. J Law Med Ethics 42:171–182. https://doi.org/10.1111/jlme.12133
Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med 14:73. https://doi.org/10.1186/s12916-016-0623-5
Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14:717–734. https://doi.org/10.1038/nrclinonc.2017.101
Fu H et al (2018) Identification and validation of stromal Immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder. Cancer Clin Cancer Res 24:3069–3078. https://doi.org/10.1158/1078-0432.CCR-17-2687
George S et al (2017) Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine. Leiomyosarcoma Immunity 46:197–204. https://doi.org/10.1016/j.immuni.2017.02.001
Ghasemi A, Zahediasl S (2012) Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab 10:486–489. https://doi.org/10.5812/ijem.3505
Hardcastle J et al (2017) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro-Oncology 19:493–502. https://doi.org/10.1093/neuonc/now179
Hazra A, Gogtay N (2016) Biostatistics series module 3: comparing groups: numerical variables. Indian J Dermatol 61:251–260. https://doi.org/10.4103/0019-5154.182416
Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L, Ye G, Deng H, Mou T, Cai S, Zhou Z, Liu H, Chen G, Li G, Qi X (2018) ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer. Ann Surg 267:504–513. https://doi.org/10.1097/SLA.0000000000002116
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16:582–598. https://doi.org/10.1038/nrc.2016.73
Kim J, Bae JS (2016) Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators inflamm 2016:6058147. https://doi.org/10.1155/2016/6058147
Lee K, Hwang H, Nam KT (2014) Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer. Gut Liver 8:131–139. https://doi.org/10.5009/gnl.2014.8.2.131
Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF (2008) Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genet 1:52. https://doi.org/10.1186/1755-8794-1-52
Leonardi GC et al (2012) The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 40:1733–1747. https://doi.org/10.3892/ijo.2012.1408
Li JQ et al (2019) A multi-element expression score is a prognostic factor in glioblastoma multiforme. Cancer Manag Res 11:8977–8989. https://doi.org/10.2147/cmar.s228174
Luoto S, Hermelo I, Vuorinen EM, Hannus P, Kesseli J, Nykter M, Granberg KJ (2018) Computational characterization of suppressive immune microenvironments in glioblastoma. Cancer Res 78:5574–5585. https://doi.org/10.1158/0008-5472.CAN-17-3714
Maccio A, Madeddu C (2012) Inflammation and ovarian cancer. Cytokine 58:133–147. https://doi.org/10.1016/j.cyto.2012.01.015
Malmstrom A et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926. https://doi.org/10.1016/S1470-2045(12)70265-6
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399–416. https://doi.org/10.1038/nrclinonc.2016.217
Mariathasan S et al (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544–548. https://doi.org/10.1038/nature25501
Mirzal A (2014) Nonparametric Tikhonov regularized nmf and its application in cancer clustering. IEEE/ACM Trans Comput Biol Bioinform 11:1208–1217. https://doi.org/10.1109/TCBB.2014.2328342
Mohme M et al (2018) Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clin Cancer Res 24:4187–4200. https://doi.org/10.1158/1078-0432.CCR-17-2617
Newman AM et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453–457. https://doi.org/10.1038/nmeth.3337
Nishino M, Ramaiya NH, Hatabu H, Hodi FS (2017) Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol 14:655–668. https://doi.org/10.1038/nrclinonc.2017.88
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-Oncology 19:v1–v88. https://doi.org/10.1093/neuonc/nox158
Phillips HS et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173. https://doi.org/10.1016/j.ccr.2006.02.019
Piperi C, Papavassiliou KA, Papavassiliou AG (2019) Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells 8:E1398. https://doi.org/10.3390/cells8111398
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https://doi.org/10.1093/nar/gkv007
Roh W et al (2017) Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9:eaah3560. https://doi.org/10.1126/scitranslmed.aah3560
Rosenberg JE et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920. https://doi.org/10.1016/S0140-6736(16)00561-4
Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805–812. https://doi.org/10.1038/nrc3153
Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874. https://doi.org/10.1073/pnas.191367098
Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev 23:1985–1996. https://doi.org/10.1158/1055-9965.EPI-14-0275
Turley SJ, Cremasco V, Astarita JL (2015) Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 15:669–682. https://doi.org/10.1038/nri3902
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60:166–193. https://doi.org/10.3322/caac.20069
Walid MS (2008) Prognostic factors for long-term survival after glioblastoma. Perm J 12:45–48. https://doi.org/10.7812/tpp/08-027
Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA (2017) Characterization of the immune microenvironment in hepatocellular carcinoma. Clin Cancer Res 23:7333–7339. https://doi.org/10.1158/1078-0432.CCR-17-0950
Ye C, Toyoda K, Ohtsuki T (2019) Blind source separation on non-contact heartbeat detection by non-negative matrix factorization algorithms. IEEE Trans Biomed Eng. https://doi.org/10.1109/TBME.2019.2915762
Yoshihara K, Shahmoradgoli M, MartÃnez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612. https://doi.org/10.1038/ncomms3612
Yu N, Gao YL, Liu JX, Shang J, Zhu R, Dai LY (2018) Co-differential gene selection and clustering based on graph Regularized multi-view nmf in cancer genomic data genes (Basel). 9:E586. https://doi.org/10.3390/genes9120586
Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, Bin J, Liao Y, Rao J, Liao W (2019) Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res 7:737–750. https://doi.org/10.1158/2326-6066.CIR-18-0436
Zeng D et al (2018) Gene expression profiles for a prognostic immunoscore in gastric cancer. Br J Surg 105:1338–1348. https://doi.org/10.1002/bjs.10871
Zhang S et al (2018) Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns. Mol Oncol 12:1047–1060. https://doi.org/10.1002/1878-0261.12309
Funding
This study was supported by Shanghai Committee of Science and Technology (No. 15441904500) and Shanghai Municipal Science and Technology Major Project (NO. 2018SHZDZX03).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, J., Xiao, X., Zhang, X. et al. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. J Mol Neurosci 70, 738–750 (2020). https://doi.org/10.1007/s12031-020-01484-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-020-01484-0